Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Neuren Pharmaceuticals Limited ( (AU:NEU) ) has shared an announcement.
Neuren Pharmaceuticals Limited announced the quotation of 200,000 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of October 3, 2025. This move is part of the company’s strategic efforts to enhance its market presence and provide additional value to its stakeholders by leveraging financial instruments.
The most recent analyst rating on (AU:NEU) stock is a Buy with a A$21.20 price target. To see the full list of analyst forecasts on Neuren Pharmaceuticals Limited stock, see the AU:NEU Stock Forecast page.
More about Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited operates in the pharmaceutical industry, focusing on the development of therapies for neurodevelopmental disorders and neurodegenerative diseases. The company is known for its innovative approach in addressing unmet medical needs within these specialized markets.
Average Trading Volume: 544,693
Technical Sentiment Signal: Buy
Current Market Cap: A$2.62B
For a thorough assessment of NEU stock, go to TipRanks’ Stock Analysis page.